When payers and accreditation bodies align early, everyone benefits, especially patients. Our work with accreditation frameworks aims to build those bridges so cell and gene therapies become more accessible and sustainable. Early collaboration helps manage the high cost and one-time nature of these transformative treatments by setting shared expectations for accreditation, reimbursement, and long-term outcomes from the outset. This alignment reduces system friction, clarifies responsibilities, and enables smoother patient access.

Embedding accreditation readiness into reimbursement planning isn’t optional, it’s essential. By doing so, we create healthcare ecosystems where advanced therapies are not just scientific breakthroughs, but deliverable, sustainable treatments that reach the patients who need them most.

Link to article